Cowen Raises Price Target on Amicus Therapeutics (FOLD) Following Announced Deal for Scioderm

Amicus (FOLD) Worth Up to $50/Sh in a Takeover, Chardan Says; Scioderm Deal Terms Suggest Future Sale

September 3, 2015 8:17 AM EDT

While not in their model, Chardan Capital Markets sees Amicus Therapeutics (NASDAQ: FOLD) worth $25-$50 in a takeover.

Analyst Gbola Amus said while the Scioderm acquisition is value neutral to their model, the terms might hint at Amicus management's thoughts on Amicus as a potential target.

"For the deal, we found it interesting that Amicus maintained the option to pay milestones... More

Market Wrap: Crude Staves-Off Loss for August; Apple, Cisco Enter Partnership; Twitter Gains on Upgrade

August 31, 2015 5:20 PM EDT

Market wrap for August 31st

End of the Day: S&P 500 down 16.7 to 1,972.2; Dow Jones down 115.0 to 16,528.03; Nasdaq down 51.8 to 4,776.51

Market Brief: U.S. markets ended August in negative territory as China concerns weighed throughout the month.

Crude surged higher as markets tempered global production-demand imbalance willing EIA data today.

Chicago PMI fell by more than expected in August.

Crude rose 7.7 percent to $48.71 per barrel, while gold dropped just 0.1 percent to $1,131.60 per ounce.

* WTI crude oil... More

Leerink Partners Remains Bullish on Amicus Therapeutics (FOLD) Following Announced Scioderm Acquisition

August 31, 2015 2:00 PM EDT

Leerink Partners reiterated an Outperform rating on Amicus Therapeutics (NASDAQ: FOLD) following the announced acquisition of Scioderm. Scioderm is a private company developing Zorblisa (SD-101), its lead product for epidermolysis bullosa that is currently enrolling for Phase 3 trial. Data readout is expected by 1H16.... More

Notable Mergers and Acquisitions 8/31: (FOLD) (ITT) (KANG) (NX)

August 31, 2015 9:51 AM EDT

* Amicus Therapeutics (NASDAQ: FOLD) and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.

Transaction highlights

Excellent strategic fit with Amicus' patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseasesLeverages Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus' commercial, patient advocacy and medical affairs infrastructure to support a successful global... More

Amicus Therapeutics (FOLD) to Acquire Scioderm in ~$950M Deal

August 31, 2015 6:29 AM EDT

Amicus Therapeutics (NASDAQ: FOLD) and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.

Transaction highlights

Excellent strategic fit with Amicus' patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseasesLeverages Scioderm development team's EB expertise with Amicus' global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus' commercial, patient advocacy and medical affairs infrastructure to support a successful global... More